Navigation Links
Intrexon and Rentokil Enter into Research and Development Agreement to Explore a New Generation of Highly-Effective, Sustainable Pest Controls
Date:9/13/2013

GERMANTOWN, Md., Sept. 13, 2013 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today that it has agreed to a joint research and development initiative with Rentokil Initial PLC that may lead to a new generation of highly-effective and sustainable pest control product and solution.

Under the agreement, Intrexon will apply its biology and science expertise to assist Rentokil in the development of specific pest control products.  The companies will also consider exploring additional areas of commercial product research and development.  Additional terms of the agreement were not disclosed.

Intrexon's Chief Operating Officer, Krish Krishnan, said Rentokil's long history of developing innovative pest control products is invaluable to the collaboration.

"Intrexon and Rentokil share a common DNA: an unwavering commitment to producing ground-breaking solutions," Krishnan said. "The same biotechnologies that have served and benefitted our collaborations in Health and Food will be equally valuable towards advancing our goals in Intrexon's emerging Environment group."

About Intrexon Corporation
Intrexon Corporation (NYSE: XON) is a biotechnology company focused on collaborating with companies in Health, Food, Energy, and the Environment to create biologically based products that improve the quality of life and health of the planet.  Through the company's proprietary UltraVector® platform, Intrexon provides its partners with commercial-scale design and development of complex biological systems.  The UltraVector® platform enables unprecedented control over the quality, function, and performance of living cells for a wide variety of
'/>"/>

SOURCE Intrexon Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Synthetic Biologics and Intrexon Corporation Enter Worldwide Exclusive Collaboration for Infectious Diseases
2. Synthetic Biologics Reiterates that the Infectious Disease Collaboration with Intrexon Remains in Effect
3. Intrexon Corporation Raises $150 Million for Synthetic Biology Initiatives
4. Intrexon Organizes Around New Synthetic Biology Markets
5. Intrexon Announces Filing of Registration Statement For Proposed Initial Public Offering
6. Intrexon Prices Initial Public Offering
7. Intrexon Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option by Underwriters
8. DermTechs Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study
9. Pittsburgh Based ParentPlus Enters Collaboration with Vitrolife
10. Two Top Biological Imaging Centers Offer Powerful Free Online Tool to Researchers, Educators, and Public
11. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... September 17, 2014 Shimadzu ... Liquid Chromatograph (2D-LC), which offers a powerful ... matrices. The system provides a new level ... which is beneficial to scientists analyzing pharmaceutical ... natural products. , Comprehensive 2D-LC combines two ...
(Date:9/17/2014)... September 17, 2014 Immunomic Therapeutics, Inc. ... Research (SBIR) grant to support the continued preclinical development ... ITI with approximately $255,000 over one year to conduct ... of food allergy, affect over one million Americans and ... allergy. Tree nut exposure is also a risk for ...
(Date:9/17/2014)... , Sept. 17, 2014 /PRNewswire/ - SQI Diagnostics ... that develops and commercializes proprietary technologies and products for ... have been approved for trading in the ... Trading is expected to commence on September 17, 2014 ... will continue to trade on the TSX Venture Exchange ...
(Date:9/17/2014)... Angeles, CA (PRWEB) September 17, 2014 Escape ... microchip for pets which will alert owners if their pet ... using GPS from an implanted microchip in the pet’s body. ... implantable microchips for pets have been around for many years, ... and are not able to track a pet’s location or alert ...
Breaking Biology Technology:Shimadzu’s New Nexera-e Two Dimensional Comprehensive Liquid Chromatograph Empowers Laboratories to Separate Even the Most Complex Mixtures 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3Implantable Microchip for Pets with GPS Tracking - Patent Filed by Escape Alert, LLC. 2Implantable Microchip for Pets with GPS Tracking - Patent Filed by Escape Alert, LLC. 3
... CROSSE, Wis., Dec. 8, 2011  Prem Rabindranauth, MD, a heart ... in La Crosse, Wis., is using an exciting ... perform heart bypass surgery. To perform MICS, a very small ... cut through the breast bone that is needed with traditional ...
... WaferGen Biosystems, Inc. (OTCBB:WGBS), an emerging genomic analysis ... its corporate presentation at the Oppenheimer 22nd Annual Healthcare ... 2011. The Company is scheduled to present ... Time.  The presentation will be webcast live and will ...
... Therapies, Inc. (OTCQB: BRTX) ("BRT") today announced that it ... University of Utah.  Pursuant to the agreement, the University ... derived from stem cells. The agreement ... strategic collaboration between BRT and the University of Utah, ...
Cached Biology Technology:Gundersen Lutheran Offers Heart Surgery with Less Pain, Faster Recovery 2WaferGen to Present Corporate Overview at Oppenheimer Healthcare Conference 2BioRestorative Therapies Signs Material Manufacturing Agreement With University of Utah 2
(Date:9/17/2014)... Evolution and Yale University offers compelling support for the ... partially predict the likelihood of being diagnosed with mental ... life. The study analyzed medical records of 1.75 million ... 30 years, and adjusted for almost all other known ... Proceedings of the Royal Society, London B . ...
(Date:9/17/2014)... at the Catalan Institute of Oncology-Bellvitge Biomedical Research ... 5 genes differentially expressed in normal accompanying cells ... be used to classify colorectal tumors, predict the ... clinical decisions to prevent relapses. , Biomarkers ... common in our population considering both sexes. About ...
(Date:9/17/2014)... on a Carnegie expedition in Australia,s Great Barrier Reef ... since the mid-1970s. The scientists suggest that ocean acidification ... slowdown. , In a quest for historical context ... current measurements of the growth rate of a section ... more than 30 years ago. Their work is published ...
Breaking Biology News(10 mins):Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Five genes to predict colorectal cancer relapses 2Coral growth rate plummets in 30-year comparison 2
... clinical trial to test a revolutionary treatment for blindness ... (University College London). The trial, funded by the Department ... could have a significant impact on future treatments for ... and children who have a condition called Leber’s congenital ...
... are an integral part of African culture, one of ... South Africa, 21st century drug therapy is used side-by-side ... plants have been used in African medicine to treat ... of the purported benefits of many plants is still ...
... brain study, even people who seemed resilient but were close to ... 11, 2001, have brains that are more reactive to emotional stimuli ... is the finding of a new Cornell study that excluded people ... (PTSD) or major depression. One of the first studies to look ...
Cached Biology News:First clinical trial of gene therapy for childhood blindness 28 plants from South Africa may hold potential for treating high blood pressure 28 plants from South Africa may hold potential for treating high blood pressure 38 plants from South Africa may hold potential for treating high blood pressure 4Traumas like Sept. 11 make brains more reactive to fear 2
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
... Abpromise for all tested applications). ... to KLH derived from within residues 400 ... acid sequence is proprietary)(Peptide available as ... ID: 55693 Swiss ...
Perm/Wash Buffer 250 Tests...
Mouse monoclonal to OCIL ( Abpromise for all tested applications)....
Biology Products: